ANNA BERKENBLIT, M.D.
Osteopathic Medicine in Cambridge, MA
License number
Massachusetts 156977
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
35 Cambridge Park Dr., Cambridge, MA 02140
Phone
(617) 665-7796
Personal information
See more information about ANNA BERKENBLIT at radaris.comName
Address
Phone
60 Hoover Rd, Needham Heights, MA 02494
Professional information
Dr. Anna Berkenblit, Cambridge MA - MD (Doctor of Medicine)
Specialties:
Hematology, Medical Oncology, Oncology
Address:
35 Cambridgepark Dr, Cambridge 02140
(617) 665-7796 (Phone)
(617) 665-7796 (Phone)
Certifications:
Hematology, 2003, Internal Medicine, 1999, Medical Oncology, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Harvard Medical School
Graduated: 1994
Brigham and Women's Hospital
Beth Israel Deaconess Med Center
Harvard Medical School
Graduated: 1994
Brigham and Women's Hospital
Beth Israel Deaconess Med Center
Head Of Clinical Research At Aveo
Position:
Head of Clinical Research at AVEO
Location:
Greater Boston Area
Industry:
Pharmaceuticals
Work:
AVEO
- Cambridge, MA since Sep 2011
-
Head of Clinical Research
Pfizer Pharmaceuticals
2009 - 2010
-
Asset Team Lead
Wyeth Pharmaceuticals
2005 - Nov 2010
-
Medical Director
Wyeth
Jan 2007 - Dec 2009
-
Medical Director
Wyeth Research
Jan 2007 - Dec 2009
-
Medical Director
Pfizer
Sep 2005 - Dec 2007
-
Associate Medical Director
Education:
Harvard Medical School 1990 - 1996
Doctor of Medicine (MD) Yale University 1986 - 1990
Doctor of Medicine (MD) Yale University 1986 - 1990
Anna Berkenblit, North Cambridge MA
Specialties:
Internist
Address:
35 Cambridgepark Dr, North Cambridge, MA 02140
Education:
Doctor of Medicine*
Board certifications:
American Board of Internal Medicine Sub-certificate in Hematology (Internal Medicine)*, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)*
Phosphatidylinositol-3-Kinase Pathway Biomarkers
US Patent:
2013018, Jul 25, 2013
Filed:
Dec 6, 2010
Appl. No.:
13/514556
Inventors:
Anna Berkenblit - Cambridge MA, US
Christina Marie Coughlin - Berwyn PA, US
Jay Marshall Feingold - Livingston NJ, US
Daniel Stephen Johnston - Collegeville PA, US
Andrew Louis Strahs - Maynard MA, US
Charles Michael Zacharchuk - Cambridge MA, US
Christina Marie Coughlin - Berwyn PA, US
Jay Marshall Feingold - Livingston NJ, US
Daniel Stephen Johnston - Collegeville PA, US
Andrew Louis Strahs - Maynard MA, US
Charles Michael Zacharchuk - Cambridge MA, US
International Classification:
A61K 39/395, A61K 45/06, A61K 31/4709
US Classification:
4241451, 435 612, 435 614, 506 9, 514313
Abstract:
Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.